stirred mixt of 13 (1.0 g, 0.0039 mole) in liquid NH  $_3$  (60 ml) and Et  $_2$ O (25 ml). After 2 lir, EtOH (5 ml) was added and the NH  $_3$  removed. The residual mixt was cooled (ice) and acidified with dil HCl. The aqueous layer was separated and extracted with Et  $_2$ O. The combined Et  $_2$ O soln was washed (saturated aqueous NaCl), dried (Na  $_2$ SO  $_4$ ), and concentrated. The residual solid was recrystallized from Skellysolve B to give 14 (0.65 g), mp 117-119°. Two recrystallizations gave analytical nuaterial: mp 120-122°; nnır (CDCl  $_3$ )  $\delta$  6.16 (m, 1 H, CH=CHCH  $_2$ ), 5.92 (nı, 1 H, CH=CHCH  $_2$ ), 4.37 (m, 1 H, >CHCO  $_2$ H), and 3.40 ppm (m, 2 H, CH=CHCH  $_2$ ).

6-Cyclohexyl-3,4-dihydro-1-naphthoic Acid (15). A soln of 14 (2.5 g) in 2 N NaOH (125 ml) was heated under reflux for 2.5 hr. The warm soln was treated with Norit, filtered, cooled, and acidified with 5 N  $\rm H_2SO_4$ . The ppt was dried and recrystallized from Skellysolve B to give 15 (1.21 g), mp 171-178°. Recrystallizations from MeOH (Norit) followed by Skellysolve B gave 15 as colorless crystals: mp 182-183°; nmr (CDCl<sub>2</sub>)  $\delta$  7.80 (d, 1 H, ArH), 7.30 (t, 1 H, vinylic), 7.04 (m, 2 H, ArH), 2.55 (broad m, 5 H, allylic and benzylic), and 1.55 ppm [broad m, 10 H, (CH<sub>2</sub>)<sub>5</sub>].

Acknowledgments. We thank Dr. Max E. Bierwagen and Dr. A. W. Pircio for permission to quote the pharmacological data, and the analytical and spectroscopic groups for their services.

## References

 P. F. Juby, W. R. Goodwin, T. W. Hudyma, and R. A. Partyka, J. Med. Chem., 15, 1297 (1972).

- (2) P. F. Juby, R. A. Partyka, and T. W. Hudyma, C. S. Pateut 3,565,904 (1971).
- (3) Ciba S. A., Belgium Patent 740,314 (1970).
- (4) C. A. Winter, E. A. Risley, and G. W. Nuss, Proc. Soc. Exp. Biol. Med., 111, 544 (1962).
- (5) J. L. Marshall and T. K. Folsom, J. Org. Chem. 36, 2011 (1971)
- (6) (a) T. Mitsut and A. Tamura, Nippon Nogel Kagaku Kaishi, 25, 17 (1951); Chem. Abstr., 47, 9302b (1953); (b) M. Inaba and T. Mitsui, Bull. Agr. Chem. Soc. Jap., 20, 42 (1956); (c) R. A. Heacock, R. L. Wain, and F. Wightman, Ann. Appl. Biol., 46, 352 (1958); (d) T. Fujita, S. Imai, K. Koshimizu, T. Mitsui, and J. Kato, Nature (London), 184, 1415 (1959); (e) K. Kawazu. T. Fujita, T. Mitsui, J. Kato, and M. Katsumi, ibid., 187, 694 (1960); (f) T. Fujita, K. Koshimizu, S. Imai, T. Mitsui, and J. Kato, Agr. Biol. Chem., 25, 710 (1961); (g) T. Fujita, K. Kawazu, T. Mitsui, M. Katsumi, and J. Kato, ibid., 30, 1280 (1966); (h) T. Fujita, K. Kawazu. T. Mitsui, and M. Katsumi, Phytochemistry, 6, 889 (1967).
- (7) (a) K. Kawazu, T. Fujita, and T. Mitsui, J. Amer. Chem. Soc.,
  81, 932 (1959); (b) A. Fredga, Chem. Ber., 89, 322 (1956).
- (8) E. C. Horning and A. F. Finelli, "Organic Syntheses," Collect. Vol. IV, Wiley, New York, N. Y., 1963, p 461.
- (9) E. C. Horning and A. F. Finelli, ref 8, p 776.
- (10) E. Testa, A. Bonatti, G. Pagani, and E. Gatti, Justus Liebigs Ann. Chem., 647, 92 (1961).
- (11) H. A. Lloyd and E. C. Horning, J. Amer. Chem. Soc., 76, 3651 (1954).
- (12) A. Bayer, Justus Liebigs Ann. Chem., 266, 169 (1891).

## Folic Acid Analogs. Modifications in the Benzene-Ring Region. 2. Thiazole Analogs<sup>†</sup>

Eugene C. Roberts\* and Y. Fulmer Shealy

Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama 35205. Received June 19, 1972

Two thiazole analogs of folic acid, in which the benzene ring is replaced by a thiazole ring, were synthesized as part of a continuing program to design and obtain folic acid analogs with a potentially altered ability to function as one-carbon transfer agents. The reductive condensation of 2-acetamido-6-formyl-pteridin-4(3H)-one (3) with diethyl N-[(2-amino-4-thiazolyl)carbonyl]glutamate (2) followed by hydrolysis of the blocking groups afforded thiazole analog 6. Thiazole analog 10 was obtained similarly from 3 and diethyl N-[(2-amino-5-thiazolyl)carbonyl]glutamate (8). Compounds 2, 6, 8, and 10 were not active against leukemia L1210 in mice in tests on a single-dose schedule and were not cytotoxic to HEp-2 cells in culture. Analogs 6 and 10 displayed modest inhibition of Streptococcus faecalis ATCC 8043 but were noninhibitory toward pigeon liver dihydrofolate reductase.

Tetrahydrofolate derivatives serve as agents in the transfer of one-carbon units in biological systems. The manner in which certain structural alterations in the folic acid molecule may alter its capacity ultimately to function as a onecarbon transfer agent has been described.2 For example, the potential of reduced folic acid type molecules for forming one-carbon transfer agents may possibly be decreased by decreasing the electron availability at position  $10 \, (N^{10})$ . In the two folic acid analogs herein reported, in which the benzene ring is replaced by the thiazole ring, the electron availability at N<sup>10</sup> may be expected to be diminished. Additionally, because of its attachment to a five-membered instead of a six-membered ring, the geometric and spatial relationship of the carbonylglutamate moiety to the remainder of the molecule has been altered. Either or both of these structural changes may affect folic acid metabolism at stages other than, or in addition to, the reduction by dihydrofolate reductase. These folic acid analogs were synthesized as part of a continuing program whose goal is to obtain potentially useful antineoplastic agents.

Chemistry. The method of synthesis of the folic acid

†This investigation was supported by Drug Research and Development, Chemotherapy, National Cancer Institute, National Institutes of Health, NIH-71-2021.

analogs **6** and **10** is based on the method of Sletzinger, et al., <sup>3</sup> in which folic acid had been obtained via the reductive condensation of **3** with p-aminobenzoylglutamic acid in the presence of p-toluenethiol. The syntheses of 2'-azafolic acid and 3'-azafolic acid have been accomplished similarly. <sup>2</sup> Intermediate **2**, obtained by the coupling of  $1^4$  with diethyl glutamate, was condensed reductively with **3**, and the crude  $N^2$ -deacetylated product **4** was obtained. Acetylation of **4** yielded **5**, and purification was accomplished at this stage. Complete and selective hydrolysis in 0.1 N NaOH of the glutamate ester groups and the  $N^2$ - and  $N^{10}$ -acetamide functions of **5** afforded the desired thiazole analog **6**. Analog **6** was obtained more conveniently from **4** by direct hydrolysis of the ester functions.

Similarly, reductive condensation of 3 with 8, obtained by the coupling of 7b with diethyl glutamate, afforded 9. Hydrolysis of the ester functions of 9 yielded thiazole analog 10 (Scheme I).

Hydrated samples of **6** and 1**0** having satisfactory elemental analyses and uv and pmr spectral properties were obtained by DEAE-cellulose column chromatography, but tlc analysis of the analogs revealed the presence of a blue-fluorescent impurity in **6**. Its identity was established as 2-amino-6-formylpteridin-4(3*H*)-one (11) by tlc compari-

Scheme I

sons with an authentic sample in several chromatographic systems. Impurity 11 was presumed to have arisen by air oxidation of 6 during chromatography.<sup>2,5</sup> The level of occurrence of 11 in 6 was shown by comparative tlc to be less than 1%. This impurity (11) was not detected on tlc analysis of analog 10.

Biological Evaluation. Compounds 2, 6, 8, and 10 were administered on a single dose schedule to mice within 24 hr of implantation ip with  $10^5$  L1210 cells. Compounds 2 and 8, at a dose of 400 mg/kg, produced no evidence of toxicity and no increase in life-span. Analogs 6 and 10 were toxic at all doses above 75 and 100 mg/kg, respectively; at these specified doses, no significant increase  $(T/C \ge 25\%)$  in life-span was observed.

Compounds 2, 6, 8, and 10 exhibited no cytotoxicity when tested at concentrations of 1, 10, and 100 mcg/ml vs. HEp-2 cells in culture.

Compounds 6 and 10 were found to produce 50% inhibition of pigeon liver dihydrofolate reductase at concentrations of 1.9 and 1.5  $\times$  10<sup>-4</sup> M, respectively; methotrexate was 50% inhibitory at 1.4  $\times$  10<sup>-8</sup> M.

Analog 6 produced 50% inhibition of Streptococcus faecalis ATCC 8043 at a concentration of  $6.0 \times 10^{-6} M$ . In a simultaneous test, methotrexate was 1700 times more effective ( $I_{50} = 3.5 \times 10^{-9} M$ ) than 6, and tetrahydrohomofoliate was 40 times more effective ( $I_{50} = 1.5 \times 10^{-7} M$ ). Analog 10 produced 50% inhibition of Strep. faecalis at a concentration of  $2.5 \times 10^{-6} M$ ; methotrexate and tetrahydrohomofolate were, respectively, 700 and 17 times more effective than 10. Although the inhibition of Strep, faecalis by 6 and 10 is relatively modest, it is in sharp contrast to the growth-supporting activity (toward S. faecalis) previously observed<sup>2</sup> for 2'- and 3'-azafolic acids. The lack of inhibition of pigeon liver dihydrofolate reductase suggests that 6 and 10 may be exerting their modest inhibitory effect on *Strep*. faecalis by inhibiting at sites other than dihydrofolate reductase.

Analog 6 was tested<sup>6</sup> vs. *Plasmodium berghei* KBG 173 malaria in mice and was found inactive at doses of 20, 40, 80, 160, 320, and 640 mg/kg.

## **Experimental Section**

Where analyses are indicated only by symbols of the elements, analytical results obtained for those elements were within ±0.4% of theoretical values. Mp's were determined with a Kofler Heizbank (gradiently heated bar) apparatus. Pmr data were determined with a Varian A-60A spectrometer and are given in ppm downfield from Me<sub>4</sub>Si. Uv spectra were determined with a Cary Model 17 recording

spectrophotometer, and wavelengths are given in nm. Linde Type 4A molecular sieves were used to dry solvents designated anhydrous, and in certain reaction procedures where indicated. Na<sub>2</sub>SO<sub>4</sub> was used to dry soln in organic solvents, and solvent evaporations were done in vacuo. The DEAE-cellulose used was Mannex (Mann Research Laboratories) of the capacity noted. Before chromatographic use, the DEAE-cellulose was converted to the phosphate form by washing with a large excess of 0.5 M potassium phosphate buffer (pH 7.0); this was followed by washes with H<sub>2</sub>O, and with H<sub>2</sub>O containing mercaptoethanol. Soln used in elution were maintained at pH 7.0 by the use of 0.005 M potassium phosphate buffer and were 0.2 M in mercaptoethanol. Linear NaCl gradient elutions utilized 0.6 M NaCl in the reservoir and buffer soln in the mixing bottle. Isolations and washings by centrifugation were done at 1800-2000 rpm; washing by centrifugation of 6 and 10 was done with dil HC1: 3-4 drops of 1 N HC1 per 50 ml of H<sub>2</sub>O. Analytical samples reported as hydrated were handled in a dry atmosphere.

Tlc was run on Analtech, Inc., cellulose-coated plates (Cell-A), Bakerflex cellulose sheets (Cell-B), Bakerflex DEAE-cellulose sheets (Cell-DEAE), and Brinkmann's silica gel H (SGH). SGH was also used for column chromatography. Solvent systems used were: A, BuOH-AcOH-H<sub>2</sub>O (5:2:3); B, BuOH-AcOH-H<sub>2</sub>O (4:1:5, upper layer); C, 5% aqueous Na<sub>2</sub>HPO<sub>4</sub>; D, 5% aqueous NH<sub>4</sub>OH-3% aqueous NH<sub>4</sub>Cl; E, 0.5 M NaCl, 0.2 M in mercaptoethanol, in 0.005 M potassium phosphate buffer at pH 7.0; F, CHCl<sub>3</sub>-MeOH (98:2); G, CHCl<sub>3</sub>-MeOH (97:3).

Diethyl N-[(2-Amino-4-thiazolyl)carbonyl]glutamate (2). 2-Aminothiazole-4-carboxylic acid·HBr\* (1, 9.0 g, 0.04 mole) was dissolved in 1200 ml of pyridine and allowed to react with 8.25 g (0.04 mole) of DCI and 9.6 g (0.04 mole) of diethyl glutamate·HCl. After 4 days, the mixture was chilled and the ppt was removed by filtration and washed with CHCl3. The filtrate was evaporated, and the residue was triturated with CHCl3. The CHCl3 filtrate was applied to a chromatography column (SGH) which was eluted with solvent F. Impure product-containing fractions were rechromatographed. Combination of the tlc-homogeneous (SGH, solvent G) fractions afforded 2: 9.78 g, 74% yield, mp 115°; pmr (CF3CO2D) 8 7.82 (s, 1 H, C3-H); the remainder of the pmr spectrum was as expected. Anal. (C13H19N3O5S) C, H, N.

2-Aminothiazole-5-carboxylic Acid (7b). Ethyl 2-aminothiazole-5-carboxylate  $\ddagger$  (7a, 17.2 g, 0.1 mole) was dissolved in 500 ml of CH<sub>3</sub>OH, and 500 ml of aqueous 2 N KOH was added. After stirring at room temp for 3 hr, the reaction was acidified to pH 4.2 and refrigerated overnight. The crystalline solid was isolated by filtration and washed with cold CH<sub>3</sub>OH-H<sub>2</sub>O before drying (P<sub>2</sub>O<sub>3</sub>) in vacuo at 78°; 14.3 g, 99% yield; pmr (CF<sub>3</sub>CO<sub>2</sub>D)  $\delta$  8.03 (s, 1 H, C<sub>4</sub>-H). Anal. (C<sub>4</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub>S) C, H, N.

Diethyl N-[(2-Amino-5-thiazolyl)carbonyl]glutamate (8). Compd 7b (12.95 g, 0.09 mole) was dissolved in 1250 ml of pyridine and allowed to react with 18.55 g (0.09 mole) of DCI and 21.6 g (0.09 mole) of diethyl glutamate ·HCl for 2 days. The product was isolated as described for 2: 15.9 g, 53% yield; mp  $106-108^{\circ}$ ; pmr (CF<sub>2</sub>CO<sub>2</sub>D) 8 8.06 (s, 1 H, C<sub>4</sub>-H); the remainder of the pmr spectrum was as expected. Anal. (C<sub>13</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>S) C, H, N.

<sup>‡</sup>The ethyl chloromalonaldehydate, used for the preparation of 7a, was not a liquid as reported, but crystallized after distillation: bp (15 mm) 86-88° (lit. bp (14 mm) 60-104°).

N-[(2-{[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino}-4-thiazolyl)carbonyl]glutamic Acid (6). A soln of p-toluenethiol (43.5 g, 0.35 mole) in 1700 ml of anhydrous methoxyethanol was heated to vigorous reflux in a flask fitted with a  $N_2$  inlet and a reflux condenser atop a condensate trap filled with molecular sieves; the reaction was protected from atm moisture and light. The flask was flushed with  $N_2$ , and 2 (18.1 g, 0.055 mole) and 3 (11.65 g, 0.05 mole) were added. After 12-hr reflux under  $N_2$ , the cooled reaction mixture was poured into 4 l. of  $Et_2O$ , and the resulting solid was isolated by filtration and washed with  $Et_2O$ .  $Et_2O$  trituration of the total filtrate residue, obtained by evaporation, yielded more solid (14.72 g total, 58% crude yield).

The combined solids were hydrolyzed at room temp in 3500 ml of 0.1 N NaOH in a  $N_2$  atm. After 17 hr, the soln was filtered and acidified to pH 6.5, the solid was isolated by centrifugation, and the supernatant was retained. This solid was twice redissolved (dil NH<sub>4</sub>OH) and reprecipitated at pH 6.5 before discarding. The three supernatant soln of pH 6.5 were combined and acidified to pH 3.5, and the solid thus obtained was isolated and washed with dil HCl by centrifugation; after freeze-drying, the solid weighed 2.1 g.

This material was dissolved in a minimum amount of dil NH4OH, and the soln was diluted to 2000 ml and made 0.2 M in mercaptoethanol. This soln was applied to a DEAE-cellulose column (standard capacity, phosphate form, 1800-ml column volume). The column was washed with 2000 ml of 0.2 M mercaptoethanol and then eluted with 2000 ml of 0.2 M NaCl. The column was next eluted with 0.35 M NaCl; the fractions were monitored by uv absorption. The desired fractions were combined, acidified to pH 3.5 with HCl, and refrigerated. The solid was isolated and washed with dil HCl by centrifugation. It was redissolved in 1500 ml of dil NaOH containing 15 ml of mercaptoethanol, and the soln was filtered and acidified (HCl) to pH 3.5 and refrigerated. The yellow ppt was isolated and washed four times with dil HCl by centrifugation before drying (P<sub>2</sub>O<sub>5</sub>) in vacuo; 1.417 g, 6% from 3. The product was pulverized before final drying ( $P_2O_8$ ) for 24 hr at 0.5 mm:  $v_{max}$  (0.1 N HCl) 250 (22,400), 322 (8700);  $v_{max}$  (pH 7) 234 (24,300), 275 (20,300), 348 (7020);  $v_{max}$  (0.1 N NaOH) 255 (32,600), 365 (8350);  $v_{max}$  (CF<sub>2</sub>CO<sub>2</sub>D)  $v_{max}$  (0.1 N NaOH) 270 (8,1 H, NCH<sub>2</sub>), 7.92 (8,1 H,  $C_s$ -H), 9.00 (s, 1 H,  $C_\tau$ H); the remainder of the pmr spectrum was as expected; analysis of 6 by tlc on Cell-B (solvent A) produced a pattern having a uv-absorbing spot followed by a separate uv-absorbing tail; two-dimensional tlc indicated this pattern was a chromatographic artifact. On Cell-DEAE (solvent E), 6 was found to contain a major uv-absorbing component and a minor blue-fluorescent impurity; side-by-side tlc comparisons with standards at several concentrations indicated this impurity to be 11 whose amount in these samples was less than 1% (Cell-DEAE, solvent E). Anal.  $(C_{16}H_{16}N_8O_8S \cdot 1.25H_2O) C, H, N.$ 

N-[(2-{[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino}-5-thiazolyl)carbonyl]glutamic Acid (10). The reductive condensation of 8 (5.92 g, 18 mmoles) with 3 (3.82 g, 16.4 mmoles) in anhydrous methoxyethanol (700 ml) in the presence of p-toluenethiol (14.2 g, 0.115 moles) was conducted as described for 2 with 3. The cooled reaction mixture was poured into 1500 ml of  $Et_2O$ , and two portions of solid were obtained (5.75 g total).

The combined solids were hydrolyzed in 3500 ml of deaerated 0.1 N NaOH in a  $N_2$  atm. The ppt obtained by acidification of the filtered hydrolysis soln was freed of solids insoluble at pH 6.5 as before. The supernatant soln of pH 6.5 was acidified to pH 3.5,

and the solid thus obtained was isolated and washed as before.

The crude product was dissolved in dil NH<sub>4</sub>OH (2000 ml containing 15 ml of mercaptoethanol; soln pH 6.5-7), and the soln was applied to a DEAE-cellulose column (27 g, standard capacity, basic form) which was next washed with H<sub>2</sub>O containing mercaptoethanol. The column was eluted with 1.0 M NaCl until the eluate yielded no ppt on acidification (HCl) to pH 3.5. The ppt obtained by acidification of the total eluate to pH 3.5 was isolated and washed with dil HCl by centrifugation; drying (P<sub>2</sub>O<sub>5</sub>) in vacuo yielded 927 mg of a yellow powder.

The yellow material was dissolved in dil NH<sub>4</sub>OH (2000 ml containing 300 ml of mercaptoethanol; soln pH 6.5), and this soln was applied to a DEAE-cellulose column (31 g, standard capacity, phosphate form); the column was washed with H<sub>2</sub>O containing mercaptoethanol before elution with a linear NaCl gradient (3000 ml total vol). The desired fractions were treated as before, and the yellow solid thus obtained weighed 377 mg; 5% yield from 3. The product was pulverized before final drying (P<sub>2</sub>O<sub>5</sub>) for 24 hr at 0.5 mm; uv<sub>max</sub> (0.1 N HCl) 250 (15,200), 281 (20,600), 320 (9650); uv<sub>max</sub> (pH 7) 279 (18,800), 302 (20,800), 342 (7920); uv<sub>max</sub> (0.1 N NaOH) 255 (24,300), 303 (20,400), 364 (9220); pmr (CF<sub>3</sub>CO<sub>2</sub>D)  $\delta$  5.15 (s, 2 H, NCH<sub>2</sub>), 8.27 (s, 1 H, C<sub>4</sub>'-H), 9.05 (s, 1 H, C<sub>7</sub>-H); the remainder of the pmr spectrum was as expected. Analysis of 10 by tlc on Cell-B (solvents A, B, C, D) and Cell-DEAE (solvent E) indicated it to be homogeneous. Anal. (C<sub>16</sub>H<sub>16</sub>N<sub>5</sub>O<sub>6</sub>S·1.5H<sub>2</sub>O) C, H, N.

Acknowledgment. The authors are indebted to Dr. W. C. Coburn, Jr., and members of the Molecular Spectroscopy Section of Southern Research Institute for the spectral and microanalytical data reported, to Dr. W. R. Laster, Jr., for the leukemia L1210 *in vivo* testing results, to Dr. L. J. Wilkoff for the cytotoxicity data, to Dr. R. F. Pittillo for the bacteriological testing, and to Miss Suzanne Straight for the enzymological testing. The antimalarial testing was conducted by L. Rane and coworkers, Malaria Screening Laboratory, University of Miami, Miami, Fla., and the results were supplied by Walter Reed Army Institute of Research, Washington, D. C.

## References

- M. Friedkin, Annu. Rev. Biochem., 32, 185 (1963); F. M. Huennekens in "Biological Oxidations," T. P. Singer, Ed., Wiley, New York, N. Y., 1968, pp 439-513.
- (2) E. C. Roberts and Y. F. Shealy, J. Med. Chem., 14, 125 (1971).
- (3) M. Sletzinger, D. Reinhold, J. Frier, M. Beachem, and M. Tishler, J. Amer. Chem. Soc., 77, 6365 (1955).
- (4) J. M. Sprague, R. M. Lincoln, and C. Ziegler, *ibid.*, 68, 268 (1946).
- (5) J. M. Whiteley, J. Drais, J. Kirchner, and F. M. Huennekens, Arch. Biochem. Biophys., 126, 955 (1968).
- (6) T. S. Osdene, P. B. Russell, and L. Rane, J. Med. Chem., 10, 431 (1967).
- (7) O. Dann, Chem. Ber., 76, 424 (1943).
- (8) A. Dornow, F. Boberg, and L. Schürer, Arch. Pharm. (Weinheim), 286, 494 (1953).